Eli Lilly Stock Falls After Analyst's Bearish Call: Here's Our Take
Eli Lilly shares fell 6% on Tuesday and are on track for their worst day since February after a downgrade…
Eli Lilly shares fell 6% on Tuesday and are on track for their worst day since February after a downgrade…
Jim Cramer explained Tuesday morning why the Investment Club is trying to strike a delicate balance with its moves during…
Jim Cramer's advice to investors dealing with the fallout from the US-Israeli attack on Iran: be selective. With stocks initially…
We added a new Bullpen name during Friday's monthly meeting, and it has minimal economic sensitivity and faces little to…
Danaher's days in the portfolio may be numbered. We were once again disappointed after Danaher's latest acquisition plan failed to…
Jim Cramer says not to worry about Novo Nordisk's lead over Club that has Eli Lilly in the obesity pill…
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does it too. Life sciences stocks are…
Eli Lilly investors have received some very good news in recent months, with one notable exception regarding the stock's performance.…
Life sciences company Danaher certainly hasn't been an easy stock to buy this year. A wave of new companies going…
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…